Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Treat Colon/Colorectal Cancer

Articles with lock require a subscription to GLG News | Request a free trial
June 9, 2008
Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
June 6, 2008
Transgene's TG4010 Vaccine for Lung Ca - Add it to the List...
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Transgene's TG4010 vaccine has a fairy elegant two-gene design.  It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer.  More mature survival data will be ready by year's end.  Phase III study is being planned.  ...
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 4, 2008
Antisoma's ASA404: Another Anti-Angiogenesis Agent to Watch
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research.  The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective. 
June 3, 2008
Genentech’s Avastin Appears Safe in Early Colon Cancer
Analysis of: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. | www.abstract.asco.org
Author: GLG Expert Contributor
While chemo plus Avastin is the standard of care for first treatment of advanced colon cancer, chemotherapy alone is used for most early colon cancer. This large study demonstrates the relative safety of adding Avastin to chemo in the early - adjuvant – setting.
June 3, 2008
Continuing Genentech's Herceptin - Confirming What We Suspected
Analysis of: Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Many of us oncologists have been in the practice of continuing  Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug.  Now, this randomized study gives data to back up that practice.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
Can Glaxo’s Affymetrix Microarray Predict Who Will Benefit from its MAGE-A3 Immunotherapy?
Analysis of: New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma | www.pipelinereview.com
Author: GLG Expert Contributor
This describes a potential two-step process using modern molecular biology to customize cancer therapy. First the Affymetrix Microarray analyzes tumor genes to try to identify which patients are at high risk to have a cancer recurrence following lung cancer surgery. Second, Glaxo's MAGE-A3 proprietary...
June 2, 2008
Lenalidomide is on a surge
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Lenalidomide is recently proving that its potential is not limited to myeloma, but can be used also in other B-cell malignancy settings such as lymphoma and CLL. CLL, in particular, needs light and yet efficacious treatments, particularly in the setting of pretreated (at times heavily) patients.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 660

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163